Oxygen (O 2 ) delivery, the maintenance of which is fundamental to supporting those with critical illness, is a function of blood O 2 content and flow. Here, we review red blood cell (RBC) physiology relevant to disordered O 2 delivery in the critically ill.
Hemoglobin (Hb) is formed of 2 a and 2 b polypeptide chains each carrying a heme prosthetic group, comprised of a porphyrin ring bearing a ferrous atom that can reversibly bind an oxygen (O 2 ) molecule. In the deoxygenated state, the Hb tetramer is electrostatically held in a tense (T) conformation. Binding of the first O 2 molecule leads to mechanical disruption of these bonds, an increase in free energy and transition to the relaxed (R) conformation. Each successive O 2 captured by T-state Hb shifts the Hb tetramer closer to the R state, which has an estimated 500-fold increase in O 2 affinity [17] . This concept of thermodynamically coupled 'cooperativity' in O 2 binding was first described by Bohr [18] and explains the sigmoidal appearance of the O 2 -Hb binding curve, also known as the oxy-Hemoglobin dissociation curve (ODC) ( Fig. 1) [19] . Moreover, an understanding of the allosteric influence of protein function by 'heterotropic effectors' [e.g. for Hb, O 2, which binds to the 'active' site (heme) is the homotropic ligand and all other molecules influencing the Hb$O 2 binding relationship are termed heterotropic effectors] was first achieved following the description of the variation in Hb$O 2 affinity [20] . In addition to the homotropic effects of ligand binding on quaternary conformational changes (e.g. cooperativity), primary ligand-binding affinity (O 2 ) is also affected by multiple heterotropic effectors of significant physiologic relevance. The major heterotropic effectors that influence Hb O 2 affinity are hydrogen ion (H þ ), chloride ion (Cl À ), carbon dioxide (CO 2 ) and 2,3-diphosphoglycerate (DPG) [17] . P 50 , the oxygen tension at which 50% of Hb-binding sites are saturated, is used as a standard means to quantify change in Hb$O 2 affinity and is inversely related to the binding affinity of Hb for O 2 [19] . Elevated levels of H þ , Cl À and CO 2 reduce O 2 -binding affinity (e.g. raise P 50 ). This allosteric KEY POINTS RBC dysfunction may contribute to the dysoxia commonly observed in the critically ill, by impairing delivery of RBCs to tissue (altered rheology and adhesion) or by impairing O 2 delivery from perfusing RBCs (altered p50, Bohr and Haldane shifts).
RBCs are newly appreciated to capture, process, transport and release NO in a tightly regulated fashion that links regional blood flow to metabolic demand in support of O 2 delivery homeostasis.
Likewise, malfunction of RBC-based control of vasoactive effectors may contribute to disordered perfusion commonly observed in the critically ill. , %   80   80   10  30  50  70  90  100 100 FIGURE 1. The normal whole blood oxygen equilibrium curve (OEC) [19] . P 50 is the pO 2 at which hemoglobin is half-saturated with O 2 . The principle effectors that alter the position and shape of the curve under physiological conditions are indicated.
shift in O 2 affinity, called the Bohr effect [21] , arises from the interactions among the above heterotropic effectors bound to different sites on hemoglobinall of which serve to stabilize the low-energy, lowaffinity, T-state Hb conformation [22] . This effect is achieved by complex interactions among carbonic anhydrase and the B3 membrane protein (also known as anion exchange protein 1, AE1). Specifically, carbonic anhydrase generates H þ and HCO 3 À from CO 2 encountered in the microcirculation; HCO 3 À then exchanges for Cl À across the RBC membrane through AE1. As a consequence, extraerythrocytic CO 2 is converted into intraerythrocytic HCl by the carbonic anhydrase-AE1 complex, thus acidifying RBC cytoplasm and raising p50 (lowering affinity, also termed 'right' shifting the ODC). Additionally, through the Haldane effect, CO 2 more directly lowers O 2 affinity (by binding to the N-terminus of the globin chains to form a carbamino, further stabilizing T-state Hb); carbamino formation also releases another hydrogen ion (further reinforcing the 'right shift' in ODC) [17] (Fig. 2 ) [23] . This set of reactions is reversed in the alkaline (and low CO 2 ) milieu in the pulmonary circulation, leading to increased Hb$O 2 binding affinity (lower P 50 ). In sum, this physiology vastly improves O 2 transport efficiency by enhancing gas capture in the lung and release to tissue -and does so in proportion to perfusion sufficiency (in the setting of perfusion lack, acidosis and hypercapnia improve O 2 release). Of note, this tightly regulated modulation of O 2 affinity may become impaired in the setting of critical illness [24] [25] [26] [27] and may in part explain the dysoxia commonly observed in this setting.
Less acute modulation of P 50 is achieved by DPG, a glycolytic intermediate that binds in an electrically charged pocket between the b chains of hemoglobin, which stabilizes the T conformation, decreasing O 2 affinity and elevating P 50 . DPG binding also releases protons, lowering intracellular pH and further reinforcing the Bohr effect. DPG in RBCs increases whenever O 2 availability is diminished (as in hypoxia or anemia) or when glycolytic flux is stimulated [28] . Lastly, temperature significantly influences Hb$O 2 affinity. As body temperature increases, affinity lessens (P 50 increases, ODC shifts right); the reverse happens in hypothermia. This feature is of physiological importance during heavy exercise, fever or induced hypothermia. It should be noted that clinical co-oximetry results and blood gas values are reported at 378C and not at true in-vivo temperature and can lead to either under or over estimation of true HbSO 2 % values and blood O 2 tension [29] .
RED BLOOD CELLS' BIOPHYSICAL FACTORS INFLUENCING TISSUE PERFUSION
Hemorheology describes flow and deformation properties of blood and its formed elements (RBCs, WBCs and platelets). Plasma is a Newtonian fluid (viscosity is independent of shear rate); its viscosity is closely related to protein content [30] and in critical illness, physiologically significant changes in viscosity may vary with concentration of acute phase reactants [31] [32] [33] . Whole blood, however, is considered a non-Newtonian suspension (fluidity cannot be described by a single viscosity value) [34] ; whole blood fluidity is determined by combined rheological properties of plasma and the cellular components. There is increasing evidence that pathophysiologic variation in hemorheology is a major determinant of tissue perfusion and, as such, of O 2 delivery by RBCs [35] .
The cellular components of blood, particularly RBCs, influence blood viscosity as a function of both number and deformability. RBC concentration in plasma (hematocrit) has an exponential relationship with viscosity and meaningfully diminishes tissue perfusion when Hct exceeds $60-65 [36] . RBC deformability, or behavior under shear stress, also strongly influences blood fluidity. Normal RBCs behave like fluid drops under most conditions, are highly deformable under shear and orient with flow streamlines [37] . However, during inflammatory stress, RBCs tend to aggregate into linear arrays like a stack of coins (rouleaux); fibrinogen and other acute phase reactants in plasma stabilize such aggregates, significantly increasing blood viscosity -such a FIGURE 2. The quantitative behavior of the carbaminohemoglobin (HbCO 2 ) dissociation curves at various oxygen tension levels [23] .
change in viscosity is most impactful upon O 2 delivery during low-flow (e.g. low shear) states (such as in critical illness) in the microcirculation [38] . RBC biomechanics and aggregation impact blood viscosity, strongly influencing the volume and distribution of O 2 delivery (again more so, in the low-shear microcirculation, or when vessel tone is abnormal) [34] . This hemorheologic physiology is perturbed by oxidative stress (common in critical illness) [39, 40] and in sepsis [41] [42] [43] [44] [45] [46] . This has been attributed to increased intracellular 2,3-DPG concentration [47] , intracellular free Ca 2þ [48] and decreased intraerythrocytic ATP with subsequent decreased sialic acid content in RBC membranes [49] . Both increased direct contact between RBCs and WBCs and reactive oxygen species released during sepsis have also been shown to alter RBC membrane properties [50, 51] . Blood viscosity and subsequent tissue blood flow is altered in several pathophysiological states. A well-known example is catecholamine discharge, which, under acute stressful conditions, reduces circulating blood volume and elevates blood pressure. The resultant fluid shift leads to a higher hematocrit, increased plasma protein and overall increase in blood viscosity. Catecholamine discharge also increases the absolute circulating RBC mass secondary to reintroduction of the 'reserve' RBC volume from the splanchnic circulation [52] .
Under normal conditions, RBC adherence to endothelial cells is insignificant and RBC deformability permits efficient passage through the microcirculation. Again, under normal conditions, enhanced endothelial cell adherence plays a role in removing senescent RBCs in the spleen. However, during critical illness, RBC-endothelial interactions are altered by RBC injuries associated with sepsis [43, 44, 53, 54] or oxidative stress [40] (more so, with 'activated' endothelium, as occurs in critical illness) [54] [55] [56] and such RBC-endothelial aggregates create a physiologically significant increase in apparent blood viscosity [34] . Moreover, RBC adhesion directly damages endothelium [57] [58] [59] [60] and augments leukocyte adhesion [61] [62] [63] [64] , further impairing apparent viscosity and microcirculatory flow. This phenomenon is commonly appreciated in the pathophysiology of vaso-occlusive crises in sickle cell disease patients [65] , malaria [66] , diabetic vasculopathy [67] , polycythemia vera [68] and central retinal vein thrombosis [69] , but may be more widespread than originally appreciated.
INFLUENCE OF RED BLOOD CELL SIGNALING UPON TISSUE PERFUSION
Normal physiologic regulation of microcirculatory blood flow instantaneously matches O 2 delivery to metabolic demand and is exquisitely responsive to change in O 2 consumption across tissue region and within regions, across time [70] . This programmed physiological response to relative tissue hypoperfusion [71] (e.g. hypoxic vasodilation; HVD) is affected in a fashion that suggests the presence of an O 2 sensor, detecting point-to-point variations in arteriolar O 2 content, and subsequently initiating a signaling mechanism capable of immediate modulation of vascular tone. Stein and Ellsworth [72] originally identified Hb as a potential circulating O 2 sensor, a fact later established in vivo following the discovery that HbSO 2 , rather than plasma or tissue pO 2 , directly correlated with blood flow [73] . RBCs were thus identified as vascular control elements that actively coordinate modulation of blood flow to resolve perfusion insufficiency (rather than simple transporters without a role in regulatory signaling). To date, three HbSO 2 -dependent RBCderived signaling mechanisms have been proposed: formation and export of S-nitrosothiols, 'catalyzed' by hemoglobin (SNO-Hb hypothesis) [74, 75] ; reduction of nitrite to NO by deoxygenated Hb (nitrite hypothesis) [76] ; and hypoxia-responsive release of ATP (ATP hypothesis) [77] . Each (probably nonexclusive) mechanism has been described to play a role in blood flow maldistribution during various pathologic states and this newly appreciated feature of RBC physiology is centrally relevant to understanding tissue dysoxia in the critically ill.
Mechanistic appreciation of the above physiology has been achieved only after a fundamental shift in our understanding of NO biology and chemistry and this issue requires some attention here. Since the original identification of NO as endothelium-derived relaxing factor (EDRF) [78, 79] , our understanding of NO-based vascular signaling has advanced considerably [80, 81] . The apparent brief lifetime and fate of EDRF were originally explained by facile diffusion of NO 'gas' in solution and its rapid terminal reactions in vascular smooth muscle cells with the ferrous heme iron (Fe 2þ ) of soluble guanylate cyclase (sGC), and in the vessel lumen with oxygenated Hb (forming MetHb and nitrate), deoxygenated Hb (forming nitrosyl hemoglobin) and superoxide (forming peroxynitrite) [82] . We have since come to appreciate the much broader biological chemistry of endothelial NO [83] , a large portion of which we now understand to occur through the covalent binding of NO þ to cysteine thiols, forming S-nitrosothiols (SNO). SNO signaling follows oxidation of NOS-generated NO radicals to a NO þ (nitrosonium) equivalent, which can then cascade across thiols in peptides and proteins to regulate protein function in a tightly regulated fashion by enzymatic trans-S-nitrosylation reactions (akin to phosphorylation [84] [85] [86] ), thereby preserving NO bioactivity [80, 81] (in fact, Hb was the first described protein to catalyze S-transnitrosylation reactions and it is this function that is essential to regulation of blood flow by RBCs) [74,87-89,90 & ]. This far broader signaling repertoire enabled an awareness that heme in sGC is not the sole (or even the principal) target of NO generated by endothelium, with a wide array of alternative sGC (cyclic guanosine monophosphate)-independent reactions following endothelial NOS (eNOS) activation [83, 84] .
To recognize the central importance of vasoregulation by RBCs, it is essential to appreciate that it is now broadly accepted that (contrary to the original paradigm) endothelium-derived NO plays no direct role in the HVD response that underlies blood flow regulation [73, 91] . In fact, because of substrate (O 2 ) limitation, NO production by eNOS is most likely attenuated by hypoxia [92, 93] . Moreover, NOS inhibitors do not block the acute change in blood flow coupled to Hb desaturation [94] . However, NO groups captured, transported, processed and subsequently deployed by RBCs do originally arise from eNOS [74] and perhaps other NOS isoforms [95] and nitrite [96] . As such, eNOS-derived NO groups are transported by RBCs to affect HVD at a time and place remote from the original site of NO synthesis, initiating immediate modulation of vascular tone in concert with cues perfusion insufficiency, including hypoxia, hypercarbia and acidosis [74, 75] .
PROCESSING AND EXPORT OF S-NITROSOTHIOLS BY RED BLOOD CELLS
The discovery that Hb could sustain S-nitrosylation (HbSNO) [74] , later characterized by both mass spectrometry [97] and X-ray crystallography [98] , provided an explanation as to how NO could circumvent terminal reactions with Hb. Rather than acting solely as scavengers of NO (as originally described), this chemistry enables RBCs to conserve NO bioactivity, allowing its transport throughout the circulation (Fig. 3) [74,75,90 & ]. The formation and export of NO groups by Hb are governed by the transition in Hb conformation that occurs in the course of O 2 loading/unloading during arteriovenous (A-V) transit [74, 75, 99, 100] . In a tightly regulated fashion, Hb captures and binds NO at its ß-hemes and subsequently converts ß-heme NO into Cys-ß93-SNO [101] . The passing of NO between heme and thiol requires heme-redox coupled activation of the NO group, which is controlled by its allosteric transition across the lung [87] . NO group export from Hb occurs when steep O 2 gradients are encountered in the periphery (HVD). This promotes NO transfer to receptor thiols, including those associated with the erythrocytic membrane protein AE-1 (band 3) [102] and extraerythrocytic thiols [89, 103] to form plasma or other cellular SNOs, which are vasoactive at low nanomoles per liter concentrations [74, 75] . Importantly, all NO transfers in this process involve NO þ [74, 104] , which protects bioactivity from Fe 2þ heme recapture or inactivation (S-nitrosothiols are the only known endogenous NO compounds that retain bioactivity in the presence of Hb [74, 103, 105] ). Extensive evidence supports SNO-Hb biology, whereby RBCs exert graded vasodilator and vasoconstrictor responses across the physiological microcirculatory O 2 gradient. RBCs dilate preconstricted aortic rings at low pO 2 (1% O 2 ), while constricting at high pO 2 (95% O 2 ) [75, 99, 105, 106] . The vasodilatory response at low O 2 is enhanced following the addition of NO (or SNO) to RBCs, commensurate with SNO-Hb formation [74, 102, 105, 107] . Additionally, the vasodilatory response is enhanced in the presence of extra cellular free thiol [105] , occurs in the absence of endothelium [104, 105] (which is consistent with in-vivo observation that HVD is endothelium independent [108] ) and transpires in the time frame of normal circulatory transit (is effected over seconds), as confirmed by measurements of A-V gradients in SNO-Hb [74, 89, 99, 106] . Finally, numerous groups have demonstrated that the bioactivity of inhaled NO is commensurate with SNO-Hb formation [109] [110] [111] [112] [113] [114] .
METABOLISM OF NITRITE BY RED BLOOD CELLS
Nitrite, long viewed as an inactive end product of NO metabolism [115] , has recently been identified as another potential store of bioactive NO in the circulation [116] . The rationale for this proposal relies on the reduction of nitrite to (and subsequent export of) NO radical by RBCs. Several RBC nitrite 'reductases' have been identified, including Hb [116] [117] [118] , xanthine oxidoreductase [119] and carbonic anhydrase [120] . Some have suggested that the reduction of nitrite to NO radical by deoxyHb may serve as the RBC-derived signaling mechanism regulating HVD [118, [121] [122] [123] . However, this hypothesis has two major shortcomings in terms of known NO chemistry/biochemistry and HVD physiology. Firstly, to influence vascular tone, the NO radical produced from nitrite must escape RBCs at low O 2 tension to elicit a vasodilatory response. Established experimental evidence, however, unambiguously refutes the possibility of NO escaping RBCs as an authentic radical, especially given the proximity, high concentration and rapid reaction kinetics (10 7 M À1 s À1 ) of authentic NO with deox-yHb. The only plausible reconciliation of this chemistry enabling bioactivity from deoxyHb-catalyzed nitrite reduction would be that bioactivity instead derives from heme-captured NO (HbFe 2þ NO) being further converted into SNO-Hb [96, 101] . The second shortcoming relates to the fact that the nitrite reductase activity of deoxyHb is in fact symmetrical across the physiological O 2 gradient [123, 124] , with maximal activity occurring at Hb p50 (the pO 2 at which Hb is 50% O 2 saturated, which for intraerythrocytic Hb in vivo is $27 mmHg) [122, 123] . This pO 2 does not align with peak HVD response, which, also of course, increases in a steadily graded fashion as pO 2 falls in the physiological range from 100 mmHg down to approximately 5 mmHg (HbSO 2 $1-2%) [71, 73] . Instead, if RBC-based vasoactivity was maximal at Hb p50, then blood flow would be diverted away from regions with pO 2 <27 mmHg (where it would be needed most). Additionally, based upon the symmetry of Hb nitrite reductase activity at the p50, RBCs traversing vascular beds with pO 2 at p25 or p75 (or p10 and p90, etc.) would generate equal NO-based activity [121] , where, in fact, gradually progressive (rather than equal) HVD responses are observed. ATP ATP (but not its degradation products ADP, AMP or adenosine [125 & ]) has long been known to act as an endothelium-dependent vasodilator in humans [77] , binding to P 2 Y purinergic receptors to induce local vascular tone [126, 127] conducted vasodilation [128, 129] via stimulation of vasoactive signals including endothelial NO, prostaglandins and endothelial-derived hyperpolarization factors. More recently, RBCs have been identified as potential sources of vascular ATP [77, 130, 131] , with release being stimulated by conditions associated with diminished oxygen supply relative to demand that is hypoxia, hypercapnia and low pH [77, 130, 132] . Despite its seeming potential as a mediator of HVD, RBC-derived ATP falls short on a couple of fronts. Firstly, HVD is unaltered by both endothelial denudation and eNOS deletion [104] ; however, ATP vasoactivity is endothelial-dependent. Second, blood levels of ATP rise and fall over minutes, which is not commensurate with the physiologic time scale for the RBC-based HVD response that occurs in the course of A-V transit over seconds. Despite its shortcomings in terms of acting as the primary mediator of HVD, it is more likely that Hb and ATP serve complementary vasoactive roles, in acute local and prolonged systemic hypoxia respectively [104, [133] [134] [135] .
CONCLUSION: BLOOD FLOW DISRUPTION DURING CRITICAL ILLNESS BY MALADAPTIVE RBC-BASED SIGNALING
Evidence is mounting in support of a causal relationship between acquired RBC dysfunction and a host of perfusion-related morbidities that complicate critical illness [41,106,136- ]. Recently, it has been observed that levels of SNO-Hb are altered in several disease states characterized by disordered tissue oxygenation [106, 107, [151] [152] [153] [154] [155] [156] [157] [158] . In addition, where examined, RBCs from such patients exhibit impaired vasodilatory capacity [89, 106, 107, 155, [157] [158] [159] . These data suggest that altered RBC-derived NO bioactivity may contribute to human pathophysiology. Specifically, alterations in thiol-based RBC NO metabolism has been reported in congestive heart failure [106] , diabetes [107, 154] , pulmonary hypertension [99, 153] and sickle cell disease [155, 160] , all of which are conditions characterized by inflammation, oxidative stress and dysfunctional vascular control. Moreover, known cross-talk between SNO signaling and cellular communication via carbon monoxide [161] [162] [163] , serotonin [86, 164, 165] , prostanoids [166, 167] , catecholamines [168] [169] [170] and endothelin [171] [172] [173] may permit broad dispersal of signals generated by dysfunctional RBCs. Precise understanding of the roles of dysregulated RBC-based NO transport in the spread of vasomotor dysfunction from stressed vascular beds may open novel therapeutic approaches to a range of pathologies.
Acknowledgements

None.
Financial support and sponsorship This work was supported by NIH 1R01GM113838-01 & UL1 RR024992WUSM, American Heart Association GIA 0950133G and Children's Discovery Institute CH-LI-2013-420.
Conflicts of interest
A.D. has received research funding and/or consulting fees from: Viasys Inc., Entegrion Inc., Terumo BCT, Galleon Pharmaceuticals, Nitrox LLD, Nitric BioTherapeutics, Galera Inc., and Novartis. A.S. and S.R. have no conflicts to declare.
REFERENCES AND RECOMMENDED READING
Papers of particular interest, published within the annual period of review, have been highlighted as:
